BioSpace News Archive

Oral Administration of APX3330 Reduced Neovascularization in a Pre-Clinical Mouse Model of Laser-Induced Choroidal Neovascularization New Data from Physiological-Based Pharmacokinetic (PBPK) Model Supports APX3330 Oral Dose for the Ongoing ZETA-1 Phase 2 Trial

OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2021, as well as discuss financial guidance, after the close of the U.S. financial markets on Wednesday, April 28, 2021.

Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced today that the first patient has been dosed in an investigator-initiated Phase 2 study to assess the efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa (RDEB)-associated locally advanced/metastatic squamous cell carcinoma (SCC).

In the food industry, the control of microbes, such as bacteria or viruses, often requires the addition of synthetic chemicals. Yet consumer demand for natural antimicrobial products is growing.

Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company’s financial results and business highlights for the first quarter ended March 31, 2021 as follows:

Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, April 29, 2021 to report its first quarter 2021 financial results and provide a corporate update.

The Broad Institute of MIT and Harvard announced that renowned technologist, entrepreneur and philanthropist Eric Schmidt will become the next Chair of the Board of Directors, succeeding Louis V. Gerstner, Jr., who has served as Chair of the Board since 2013.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for serious rare and ultra-rare diseases, announced today the appointment of Kim Sablich to its Board of Directors.

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2021 financial results on Thursday, May 6, 2021 .

DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced the publication of a study entitled “A Rapid SARS-CoV-2 Variant Detection by Molecular-Clamping Based RT-qPCR” in MedRxiV (https://doi.org/10.1101/2021.04.01.21254484)